TRUE Private Wealth Advisors increased its stake in Eli Lilly and Company (NYSE:LLY) by 57.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,722 shares of the company’s stock after acquiring an additional 8,616 shares during the period. TRUE Private Wealth Advisors’ holdings in Eli Lilly and were worth $2,029,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC boosted its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and during the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and during the second quarter valued at approximately $129,000. Point72 Asia Hong Kong Ltd boosted its position in shares of Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new stake in shares of Eli Lilly and in the second quarter valued at approximately $148,000. Institutional investors own 76.43% of the company’s stock.
In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the sale, the insider now directly owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 628,588 shares of company stock worth $53,399,536. 0.20% of the stock is owned by corporate insiders.
Shares of Eli Lilly and Company (LLY) opened at $86.45 on Friday. The firm has a market cap of $94,551.04, a price-to-earnings ratio of 21.00, a PEG ratio of 1.89 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 1-year low of $67.22 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.41%. The ex-dividend date was Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
A number of brokerages recently issued reports on LLY. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday. Morgan Stanley boosted their price target on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Leerink Swann boosted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $90.25.
COPYRIGHT VIOLATION WARNING: “TRUE Private Wealth Advisors Raises Stake in Eli Lilly and Company (LLY)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://transcriptdaily.com/2017/12/09/true-private-wealth-advisors-raises-stake-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.